Minerva Neurosciences, Inc. (NERV)
2.32
+0.08
(+3.57%)
USD |
NASDAQ |
Oct 30, 16:00
2.30
-0.02
(-0.86%)
After-Hours: 20:00
Minerva Neurosciences Enterprise Value : 105.94M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 105.94M |
| October 29, 2026 | 102.16M |
| October 28, 2026 | 100.75M |
| October 27, 2026 | 101.69M |
| October 26, 2026 | 100.27M |
| October 23, 2026 | 105.00M |
| October 22, 2026 | 109.72M |
| October 21, 2026 | 109.25M |
| October 20, 2026 | 115.86M |
| October 19, 2026 | 105.94M |
| October 16, 2026 | 107.36M |
| October 15, 2026 | 110.66M |
| October 14, 2026 | 107.36M |
| October 13, 2026 | 115.15M |
| October 12, 2026 | 132.86M |
| October 09, 2026 | 146.56M |
| October 08, 2026 | 148.45M |
| October 07, 2026 | 150.81M |
| October 06, 2026 | 158.36M |
| October 05, 2026 | 153.17M |
| October 02, 2026 | 151.28M |
| October 01, 2026 | 148.92M |
| September 30, 2026 | 154.59M |
| September 29, 2026 | 154.59M |
| September 28, 2026 | 156.95M |
| Date | Value |
|---|---|
| September 25, 2026 | 156.95M |
| September 24, 2026 | 159.31M |
| September 23, 2026 | 161.20M |
| September 22, 2026 | 176.31M |
| September 21, 2026 | 170.41M |
| September 18, 2026 | 169.23M |
| September 17, 2026 | 159.78M |
| September 16, 2026 | 160.96M |
| September 15, 2026 | 177.25M |
| September 14, 2026 | 185.76M |
| September 11, 2026 | 192.37M |
| September 10, 2026 | 192.84M |
| September 09, 2026 | 190.95M |
| September 08, 2026 | 202.76M |
| September 04, 2026 | 205.59M |
| September 03, 2026 | 217.87M |
| September 02, 2026 | 207.95M |
| September 01, 2026 | 207.95M |
| August 31, 2026 | 211.73M |
| August 28, 2026 | 224.95M |
| August 27, 2026 | 238.65M |
| August 26, 2026 | 252.82M |
| August 25, 2026 | 232.51M |
| August 24, 2026 | 223.54M |
| August 21, 2026 | 224.95M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Heron Therapeutics, Inc. | 159.35M |
| Tonix Pharmaceuticals Holding Corp. | -89.32M |
| Karyopharm Therapeutics, Inc. | 206.10M |
| Corbus Pharmaceuticals Holdings, Inc. | -34.88M |
| Ocugen, Inc. | 226.18M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 17.47M |
| Total Expenses (Quarterly) | -17.47M |
| EPS Diluted (Quarterly) | -0.1379 |
| Earnings Yield | -1.24K% |
| Normalized Earnings Yield | -422.06 |